ALK gene and EML4 gene detection probe, preparing method thereof and kit
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- GUANGZHOU LBP MEDICINE SCI & TECH
- Publication Date
- 2016-05-04
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention belongs to biotechnology, and in particular relates to ALK gene and EML4 gene detection probes, preparation methods and kits thereof. Background technique
[0002] In 2014, the annual report of tumor registration indicated that lung cancer ranked first in the incidence rate (35.23 / 100,000, 19.59%) and death rate (27.93 / 100,000, 24.87%) of malignant tumors in China. The occurrence of lung cancer is considered to be a multi-step process, which is closely related to the amplification / activation of proto-oncogenes and / or the inactivation of tumor suppressor genes. opportunity for treatment. The study found that 64% of lung adenocarcinoma patients detected cancer drivers, of which 8% were ALK rearrangements. ALK gene fusion is not a favorable prognostic factor for advanced NSCLC, but crizotinib can improve the survival of ALK-positive patients. Previous studies have shown that the EML4-ALK gene fusion mutation rate is 2% to 7%. A study rep...